Compare Meta Platforms Inc (META) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs 10X Genomics Inc — how do they compare? Meta Platforms Inc trades at $581.98 (market cap $1.53T), while 10X Genomics Inc trades at $57.78 (market cap $7.61B). The key difference: Meta Platforms Inc is far larger — about 201.1× 10X Genomics Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| META | TXG | |
|---|---|---|
Market Cap | $1.53T | $7.61B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $58.57 |
52-Week Low | $525.72 | $11.34 |
Enterprise Value | $1.55T | $7.14B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $581.30, down 2.29% over 24 hours. The technical picture is neutral, with the price near key support at $580. Fundamentally, the company reported strong revenue of $200.97B for 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a significant legal ruling in Massachusetts.
The outlook is positive, supported by a strong analyst consensus (79% Buy) and a $761.95 price target. Key opportunities include AI monetization and revenue growth, while risks involve high capital expenditure, legal challenges, and competitive pressures in the social media and AI sectors.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
